WOK WORK Medical Technology Group LTD Annual reports only
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1929783 · Fiscal year ends 09/30
Financial factors as of 2025-09-30 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-14.4%
TTM net income YoY69.3%
TTM EPS YoY85.2%
Revenue 3-yr CAGR-20.6%
Net income 3-yr CAGR—
Margins
Gross margin23.8%
Operating margin—
Net margin-10.9%
FCF margin49.9%
EBITDA margin—
Returns
ROE-6.8%
ROA-3.1%
ROIC (approx.)—
Asset turnover0.28x
Leverage & solvency
Liabilities / assets36.2%
Debt / equity0.00x
Current ratio1.71x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-5.82x
Accruals ratio-21.1%
Payout ratio—
Capex / revenue13.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 | FY20232023-09-30 | FY20222022-09-30 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $9.85M | $11.51M | $13.57M | $19.71M |
| Gross profit | $2.34M | $2.87M | $4.14M | $4.42M |
| R&D expense | $435,311 | $302,511 | $301,644 | $183,900 |
| SG&A expense | $2.33M | $4.56M | $1.86M | $2.56M |
| Interest expense | $503,519 | $557,571 | $392,741 | $352,968 |
| Pretax income | -$1.08M | -$3.67M | $110,389 | $1.11M |
| Income tax | $119,053 | -$125,291 | $47,006 | $169,435 |
| Net income | -$1.07M | -$3.49M | $112,030 | $865,210 |
| EPS (basic) | -0.04 | -0.27 | 0.01 | 0.07 |
| EPS (diluted) | -0.04 | -0.27 | 0.01 | 0.07 |
| Weighted avg. shares (diluted) | 28.98M | 12.71M | 12.50M | 12.50M |
| Balance sheet | ||||
| Cash & equivalents | $4.09M | $6.56M | $1.60M | $773,422 |
| Receivables | $615,838 | $1.65M | $3.33M | — |
| Inventory | $2.46M | $3.18M | $4.62M | — |
| Current assets | $20.46M | $20.83M | $22.15M | — |
| PP&E, net | $10.59M | $11.37M | $6.63M | — |
| Intangibles | $959,116 | $1.04M | $998,450 | — |
| Total assets | $33.16M | $36.25M | $29.96M | — |
| Current liabilities | $11.97M | $20.18M | $18.92M | — |
| Short-term debt | $6.39M | $13.32M | $8.84M | — |
| Total liabilities | $11.99M | $20.18M | $18.97M | — |
| Shareholders' equity | $18.34M | $13.19M | $9.88M | $11.19M |
| Shares outstanding | — | 14.59M | 12.50M | — |
| Cash flow statement | ||||
| Operating cash flow | $6.24M | -$2.23M | $2.21M | -$2.26M |
| Capital expenditure | $1.33M | $9.23M | $455,391 | $2.01M |
| Free cash flow | $4.91M | -$11.45M | $1.75M | -$4.27M |
| Investing cash flow | -$7.61M | -$9.06M | -$583,304 | -$1.35M |
| Financing cash flow | -$898,212 | $15.66M | -$728,719 | $3.57M |
| Depreciation & amortization | $923,108 | $1.41M | $1.60M | $3.26M |
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.